| abstract |
The present invention provides a kind of candidate stem cell, the ZBTB7A gene expression amounts of the candidate stem cell are reduced or not expressed.The present invention knocks out fetal hemoglobin gene inhibiting factor using CRISPR technologies, easy to operate, takes shortï¼›Fetal hemoglobin gene inhibiting factor ZBTB7A does not influence the normal function of erythroblast after knockout, has expanded the treatment means of thalassemiaï¼›Using patient's autologous stem cell as transplant, it is entirely avoided trnasplantion immunity rejection reduces stem-cell therapy risk. |